Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256661 | 0.80 | KMT2A (0.47) | DAOHPGDNR1H2NR1H3KMT2A | |
| SCHEMBL18752226 | 0.74 | MBOAT4 (0.33) | DAOHPGDNR1H2NR1H3KMT2A | |
| SCHEMBL829871 | 0.74 | TSHR (0.36) | — | |
| SCHEMBL24258447 | 0.73 | LSS (0.32) | DAOKDM1AMAOAMAOB | |
| SCHEMBL19851266 | 0.73 | KMT2A (0.30) | KMT2A | |
| SCHEMBL19851267 | 0.73 | KMT2A (0.30) | KMT2A | |
| SCHEMBL22624373 | 0.72 | KIF11 (0.36) | NR1H2NR1H3KMT2AMAPK1 | |
| SCHEMBL10285101 | 0.71 | NPC1 (0.38) | MAOBMAPK1 | |
| SCHEMBL3235456 | 0.71 | PDE2A (0.35) | DAOHPGDKMT2AKDM1AMAOA | |
| SCHEMBL22184934 | 0.70 | KIF11 (0.47) | HPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177612-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2022-02-23 | — | — | EP | disclosed |